Pneumococcal Disease: Recommended vaccinations
  General recommendation
  Recommendation for specific groups only
  Catch-up (e.g. if previous doses missed)
 
Vaccination not funded by the National Health system
 
Mandatory vaccination
MonthsYears
2345610111213141518232356121819506064657585≥ 86
Austria
PCV
PCV
PCV
PCV1
PCV
PCV
PCV132
Belgium
PCV
PCV
PCV
PCV133
PCV134
Bulgaria
PCV
PCV
PCV
PCV5
Croatia
PCV6
PCV6
PCV6
Cyprus
PCV
PCV
PCV7
PPSV238
PPSV239
Czech Republic
PCV10
PCV10
PCV10
Pnc11
Pnc12
Denmark
PCV13
PCV13
PCV13
PPSV2313
Estonia
Finland
PCV10
PCV10
PCV10
PCV13+PPSV2314
France
PCV
PCV
PCV
Germany
PCV
PCV
PCV
PCV15
PPSV2316
Greece
PCV13
PCV13
PCV13
PCV13
PCV13
PCV13+PPSV2317
PCV13+PPSV23
PCV13+PPSV23
Hungary
PCV13
PCV13
PCV13
PPSV23
Iceland
PCV10
PCV10
PCV10
PPSV2318
Ireland
PCV
PCV
PCV
PPSV2319
Italy
PCV
PCV
PCV
PCV13+PPSV2320
Latvia
PCV
PCV
PCV
Liechtenstein
PCV13
PCV13
PCV13
Lithuania
PCV
PCV
PCV21
Luxembourg
PCV
PCV
PCV
PCV
PPSV2322
PCV13+PPSV2322
Malta
PCV
Netherlands
PCV
PCV
PCV
PPSV2323
Norway
PCV13
PCV13
PCV13
PPSV2324
Poland
PCV
PCV
PCV
PCV
Portugal
PCV13
PCV13
PCV13
Romania
PCV25
PCV25
PCV25
Slovakia
PCV
PCV
PCV
PCV26
Slovenia
PCV
PCV
PCV
PCV+PPSV2327
Spain
PCV28
PCV28
PCV28
PPSV23 / PCV+PPSV2329
PPSV2328
Sweden
PCV
PCV
PCV
PPSV2330
United Kingdom
PCV1331
PCV13
PPSV23

Footnotes:

  1. Minimum interval of 6 month after second dose
  2. If no previous vaccination, 1 dose of PPSV23 after one year. If previous vaccination with PPSV23, 1 dose of PCV13 2 years later.If previous dose of PCV13, 1 dose of PPSV23 2 year later.
  3. Pneumococcal vaccination is recommended in healthy adults from 65 to 85 years, in adults with comorbidity from 50 to 85 years, and in adults with an increased risk of invasive pneumococcal infection from 19 to 85 years. These target patients (comorbidity and adults with an increased risk of IPD) are specifically identified in the corresponding recommendations (https://www.health.belgium.be/fr/avis-9210-vaccination-antipneumococcique-adultes-fiche). Vaccine schedule for complete primo-vaccination: a single dose of PCV13, followed by PPSV23 after at least 8 weeks. If vaccination in the past with PPSV23, a single dose of PCV13 at least one year after the last PPSV23 vaccine. Booster vaccination with PPSV23 every 5 years is recommended for adults with an increased risk of IPD. Indication for a booster vaccination for the other adult risk groups should be evaluated based on the latest evidence-based data and epidemiology.
  4. Adults over 85 years: : indication for pneumococcal vaccination should be decided on an individual basis, taking into account the individual risk of pneumococcal infection and the expected/estimated immune response to the vaccine. The vaccine schedule is the same as that recommended for the other adult target groups (https://www.health.belgium.be/fr/avis-9210-vaccination-antipneumococcique-adultes-fiche).
  5. Not earlier than 6 months after the 3rd dose
  6. Introduced in 2019
  7. catch-up possible until 6 years if previous recommended doses were missed
  8. vaccines only given on specific indications
  9. no revaccination recommended
  10. Recommendation only, the vaccination is covered by the health insurance
  11. PCV for people hospitalized at long-term-illness wards and houses for seniors. Also for at-risk groups of people based in houses for people with health disability and houses with special regime.
  12. PCV for persons from 65 years of age. Recommended only. The vaccination is covered by the health insurance.
  13. PCV 13 also recommended. For recommendations from Statens Serum Institut for vaccination of people within at-risk groups refer to http://www.ssi.dk/English/News/EPI-NEWS/2014/No%2040%20-%202014.aspx. There are no official recommendations from the Danish Health and Medicines Authority for use of PPV23 or PCV 13, but there is, however, reimbursement for defined at-risk groups.
  14. Recommended but not free of charge for those over 65 years. For more information on pneumococcal vaccination policy please refer to http://www.thl.fi/fi_FI/web/rokottajankasikirja-fi/pneumokokkikonjugaattirokotukset
  15. number of doses necessary varies according to age
  16. one dose recommended, booster doses every 6 years if indicated
  17. PPSV is recommended in addition to PCV13 at least 2 months after the last dose of PCV13 in subjects > 2 years with an increased risk of disease from pneumococcal infections. A booster dose of PPSV23 is recommended 5 years after the first dose
  18. One dose is recommended for all adults over age 60. For risk groups one dose of conjugated vaccine and one dose of PPS vaccine is recommended after 2 years of age . for more information see: https://www.landlaeknir.is/servlet/file/store93/item23265/Lei%C3%B0beiningar%20um%20notkun_b%C3%B3luefna_gegn_pneum%C3%B3kokkum-final.pdf
  19. The vaccine is free of charge, but administration fees may be charged to patient (based on income and eligibility for free healthcare)
  20. one dose of PCV13 at 65 years and one dose PPSV after at least 8 weeks
  21. Can be administered concomitantly with MMR
  22. It is recommended that populations at risk and elderly 65 years of age and over receive a dose of 13-valent pneumococcal conjugate vaccine (PCV13) followed, 8 weeks later, by a dose of 23-valent pneumococcal polysaccharide vaccine (PCV23). In the present state of knowledge, the CSMI recommends a PPV23 recall only in people at risk, who are recalled every 5 years. Children at risk of invasive pneumococcal infection are also affected by this recommendation: in the absence of previous vaccination with PCV13, catch-up is indicated. For mopre informeation: http://www.sante.public.lu/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/infection-pneumocoques/index.html
  23. Implementation starting from fall 2020. Vaccination recommended for healthy adults aged 60 to 75 years. First dose at 60 years followed by booster doses every 5 years with a last dose at 75 years. More information available at: https://www.rivm.nl/pneumokokken/pneumokokkenvaccinatie-voor-ouderen
  24. One dose if not vaccinated in the previous 10 years. Reimbursed for some at-risk groups.
  25. Pneumococcal conjugate vaccine will be included in the national vaccination calendar depending on available funds
  26. Recommended to all. Mandatory to persons residing in social care facilities
  27. PCV and PPSV23 recommended, self-paid
  28. For recommendations in children and adults with high risk conditions Please refer to https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/VacGruposRiesgo/docs/VacGruposRiesgo_todas_las_edades.pdf
  29. For recommendations in children and adults with high risk conditions, refer to: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/VacGruposRiesgo/docs/VacGruposRiesgo_todas_las_edades.pdf
  30. Funding varies by region
  31. Recommended at 12 weeks